You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B-lymphocytes

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

JAK-i on RA B-lymphocytes Tolerance and Disease Resolution

Recruiting
  • Rheumatoid Arthritis
  • B lymphocyte profiling
  • Rome, Italy
    Division of Clinical Immunology, Fondazione Policlinico Universi
Feb 22, 2023

Digestive System Malignant Solid Tumors Trial (ScTIL injection, ScTIL injection and B lymphocytes adjuvant)

Not yet recruiting
  • Digestive System Malignant Solid Tumors
  • ScTIL injection
  • ScTIL injection and B lymphocytes adjuvant
  • (no location specified)
Feb 7, 2023

Scleroderma, Systemic Trial in Lille (skin biopsy, Blood punction)

Recruiting
  • Scleroderma, Systemic
  • skin biopsy
  • Blood punction
  • Lille, France
    Hôpital Claude Huriez, CHU
Oct 4, 2021

Myasthenia Gravis, Generalized Trial in Roma (Rituximab, Placebo)

Recruiting
  • Myasthenia Gravis, Generalized
  • Roma, Italy
    Policlinico A. Gemelli IRCCS
May 25, 2023

Isolation of Human Recombinant Therapeutic Monoclonal

Recruiting
  • Pseudomonas Aeruginosa
  • Multi-antibiotic Resistance
  • Isolation of anti-Pseudomonas antibodies from type B lymphocytes
  • Grenoble, France
    Chu Grenoble Alpes
May 6, 2022

Cellules B et Microbiote Dans le SNI

Not yet recruiting
  • Microbiota
  • +3 more
  • Measurement of blood immune populations and microbiota distribution.
  • Nantes, Loire-Atlantique, France
    Nantes University Hospital
Jan 10, 2022

Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection Trial in Beijing (Rituximab

Recruiting
  • Secondary Hemophagocytic Lymphohistiocytosis
  • Chronic Active Epstein-Barr Virus Infection
  • Rituximab Monotherapy
  • Beijing, China
    Zhao Wang
May 18, 2022

Mechanistic Studies of Teriflunomide in RRMS

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Ann Arbor, Michigan
    University of Michigan
Jul 27, 2022

Kidney Transplantation Trial (Extracorporeal phototherapy)

Not yet recruiting
  • Kidney Transplantation
  • Extracorporeal phototherapy
  • (no location specified)
Apr 28, 2021

Acute Lymphocytic Leukemia, Lymphoma Trial in New York (Biological/Genetically Modified T cells, Cyclophosphamide-based chemo)

Active, not recruiting
  • Acute Lymphocytic Leukemia
  • Lymphoma
  • Biological/Genetically Modified T cells
  • Cyclophosphamide-based chemotherapy
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 3, 2023

Malignant Hyperthermia: Ambispective Cohort.

Recruiting
  • Hyperthermia, Malignant
  • In vitro contracture test (IVCT)
  • +2 more
  • Madrid, Spain
    Hospital Universitario La Paz
Jan 12, 2022

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome Trial in Cleveland

Not yet recruiting
  • Allogeneic Stem Cell Transplant Candidate
  • +4 more
  • Cellular therapy product
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Jul 1, 2022

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

HIV-1-infection, AIDS Trial in Ho Chi Minh City (Ahah Drug, Ahah Placebo)

Completed
  • HIV-1-infection
  • AIDS
  • Ahah Drug
  • Ahah Placebo
  • Ho Chi Minh City, Vietnam
    Saigon Biopharma Company Limited
Feb 24, 2021

Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic

Not yet recruiting
  • Recurrent Transformed Chronic Lymphocytic Leukemia
  • +7 more
  • Biospecimen Collection
  • +9 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 15, 2023

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Tumor Infiltrating Lymphocytes, Safety, Melanoma Trial in Beijing (GC101 TIL)

Recruiting
  • Tumor Infiltrating Lymphocytes
  • +4 more
  • GC101 TIL
  • Beijing, China
    Beijing Cancer Hospital
Nov 7, 2023

Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease Trial in Houston (EBV-specific T cells: A, EBV-specific T

Recruiting
  • Hodgkin's Disease
  • +3 more
  • EBV-specific T cells: A
  • EBV-specific T cells: B
  • Houston, Texas
  • +1 more
Jun 28, 2022

Relapsed B-Cell Acute Lymphoblastic Leukemia Trial in Boston, New York (procedure, drug, biological)

Active, not recruiting
  • Relapsed B-Cell Acute Lymphoblastic Leukemia
  • leukapheresis or collection of PBMCs
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 26, 2022

Lymphoma, Myeloma, Leukemia Trial in Houston (Kappa CD28 T cells)

Recruiting
  • Lymphoma
  • +2 more
  • Kappa CD28 T cells
  • Houston, Texas
  • +1 more
Jan 31, 2022

DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle

Terminated
Has Results
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +5 more
  • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Trial in Houston (CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T

Recruiting
  • Non-Hodgkin's Lymphoma
  • +2 more
  • CD19.CAR-CD28Z T Cells - dose escalation 2
  • CD19.CAR-CD28Z T Cells - dose escalation 1
  • Houston, Texas
  • +1 more
Feb 10, 2022

EBV-Related Hodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Non-Hodgkin's Lymphoma Trial in Houston (Dose Level 1A:

Not yet recruiting
  • EBV-Related Hodgkin Lymphoma
  • +2 more
  • Dose Level 1A: 2 x 10^7 cells/m2
  • +4 more
  • Houston, Texas
  • +1 more
Feb 7, 2022

Breast Cancer, Colorectal Cancer, Uveal Melanoma Trial in Orlando, Pittsburgh (TBio-4101, Pembrolizumab)

Recruiting
  • Breast Cancer
  • +2 more
  • Orlando, Florida
  • +1 more
Feb 1, 2023